FDA on ENHANCE
This article was originally published in The Tan Sheet
The agency will review the recently completed study of the Merck/Schering-Plough combination cholesterol therapy Vytorin after it receives the final results, according to a Jan. 25 announcement. The study found "no statistically significant differences" between a group receiving the highest dose of Vytorin (10 mg ezetimibe plus 80 mg simvastatin) and a group receiving 80 mg simvastatin in either the primary endpoint or in key secondary imaging endpoints (1"The Tan Sheet" Jan. 21, 2008, p. 12). Investigators in the firms' ENHANCE trial determined the primary endpoint - mean change in the intima-media thickness - through ultrasound measurements of the carotid arteries. FDA said it is not clear why the lower levels of LDL cholesterol in patients who took Vytorin did not lead to lesser amounts of plaque, compared to patients treated with simvastatin alone...
You may also be interested in...
Merck and Schering-Plough will pay $5.4 million to 35 states and the District of Columbia to resolve an investigation into the firms' delayed release of negative study results for the cholesterol-lowering drug Vytorin. The agreement, which is not an admission of liability, covers the states' and D.C.'s investigative costs. The ENHANCE trial found Vytorin was no more effective in reducing plaque in carotid arteries than simvastin (1"The Tan Sheet" Feb. 4, 2008)
The Merck/Schering-Plough combination cholesterol therapy Vytorin has failed to demonstrate significant benefit over simvastatin alone in preventing formation of arterial plaque in the ENHANCE trial
In this week's podcast edition of Five Must-Know Things: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.